# EDGAR Filing Document

**Accession Number:** 0001857044
**File Stem:** 0001641172-25-026333
**Filing Date:** 2025-9
**Character Count:** 75896
**Document Hash:** f1894b7defe71011ee56abd3c80e0440
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-026333.hdr.sgml**: 20250903

**ACCESSION NUMBER**: 0001641172-25-026333

**CONFORMED SUBMISSION TYPE**: S-1/A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20250903

**DATE AS OF CHANGE**: 20250903

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Indaptus Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001857044
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 863158720
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1/A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289984
- **FILM NUMBER:** 251288574

**BUSINESS ADDRESS:**
- **STREET 1:** 3 COLUMBUS CIRCLE
- **STREET 2:** 15TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** (646) 427-2727

**MAIL ADDRESS:**
- **STREET 1:** 3 COLUMBUS CIRCLE
- **STREET 2:** 15TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Intec Parent Inc.
- **DATE OF NAME CHANGE:** 20210414

**As filed with the Securities and Exchange Commission on September 3, 2025.**

**Registration No. 333-289984**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Amendment No. 1**

**to**

**FORM S-1**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**INDAPTUS THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **2834** | **86-3158720** |
| (State or other jurisdiction of<br> incorporation or organization) | (Primary Standard Industrial<br> Classification Code Number) | (I.R.S. Employer<br> Identification No.) |

---

**3 Columbus Circle**

**15th Floor**

**New York, NY 10019**

**+1 (646) 427-2727**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Jeffrey A. Meckler**

**Chief Executive Officer**

**Indaptus Therapeutics, Inc.**

**3 Columbus Circle**

**15th Floor**

**New York, NY 10019**

**+1 (646) 427-2727**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

***Copies of all communications, including communications sent to agent for service, should be sent to*:**

---

| | |
|:---|:---|
| **Gary Emmanuel, Esq.**<br> **Greenberg Traurig LLP**<br> **One Vanderbilt Avenue**<br> **New York, New York 10017**<br> **+1 (212) 801 9337** | **Rick A. Werner, Esq.**<br> **Jayun Koo, Esq.**<br> **Haynes and Boone, LLP**<br> **30 Rockefeller Plaza, 26<sup>th</sup> Floor**<br> **New York, New York 10112**<br> **(212) 659-7300** |

---

**Approximate date of commencement of proposed sale to the public:** From time to time after this Registration Statement becomes effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

**THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933, AS AMENDED, OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE SECURITIES AND EXCHANGE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a), MAY DETERMINE.**

**EXPLANATORY NOTE**

This Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-289984) of Indaptus Therapeutics, Inc. (the "Amendment") is being filed solely for the purpose of filing Exhibit 10.31 to the Registration Statement. Accordingly, this Amendment consists of the facing page, this explanatory note, Part II of the Registration Statement (including the signature page and the exhibits index) and the filed exhibit only. The prospectus, constituting Part I of the Registration Statement, is unchanged and has therefore been omitted.

**PART II**

**INFORMATION NOT REQUIRED IN PROSPECTUS**

**Item 13. Other Expenses of Issuance and Distribution.**

The following is an estimate of the expenses (all of which are to be paid by the registrant) that we may incur in connection with the securities being registered hereby, other than the Securities and Exchange Commission registration fee and the FINRA filing fee:

---

| | |
|:---|:---|
| SEC Registration Fee | $2354 |
| FINRA Filing Fee | 2806 |
| Accounting Fees and Expenses | 20000 |
| Legal Fees and Expenses | 70000 |
| Miscellaneous Expenses | 4840 |
| Total | $100000 |

---

**Item 14. Indemnification of Directors and Officers.**

Section 145 of the Delaware General Corporation Law provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses including attorneys' fees, judgments, fines and amounts paid in settlement in connection with various actions, suits or proceedings, whether civil, criminal, administrative or investigative other than an action by or in the right of the corporation, a derivative action, if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, if they had no reasonable cause to believe their conduct was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification only extends to expenses including attorneys' fees incurred in connection with the defense or settlement of such actions, and the statute requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. The statute provides that it is not exclusive of other indemnification that may be granted by a corporation's certificate of incorporation, bylaws, agreement, a vote of stockholders or disinterested directors or otherwise.

Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws provide that we will indemnify and hold harmless, to the fullest extent permitted by Section 145 of the Delaware General Corporation Law, as amended from time to time, each person that such section grants us the power to indemnify.

The Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:

● any breach of the director's duty of loyalty to the corporation or its stockholders;

● acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;

● payments of unlawful dividends or unlawful stock repurchases or redemptions; or

● any transaction from which the director derived an improper personal benefit.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, offices or controlling persons of ours, pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of ours in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereunder, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**Item 15. Recent Sales of Unregistered Securities.**

The securities described below were sold within the past three years and were not registered under the Securities Act.

**Sales by Indaptus**

In June 2025, we completed a private placement, pursuant to which we sold and issued to certain investors, including our Chief Executive Officer, (i) convertible notes in the aggregate principal amount of approximately $5.7 million, which automatically converted into 501,566 shares of our common stock at a conversion price of $8.302 per share and pre-funded warrants to purchase 190,795 shares of our common stock, and (ii) warrants to purchase 1,384,722 shares of our common stock, immediately exercisable at $8.302 per share and expiring five years from the date of issuance. In connection with the June 2025 financing, we issued to the placement agent and its designees placement agent warrants to purchase an aggregate of 83,083 shares of common stock at an exercise price per share equal to $8.302. The placement agent warrants are immediately exercisable and expire five years from the date of issuance.

On February 12, 2025, Indaptus entered into a standby equity purchase agreement, or the SEPA, with YA II PN, LTD., or YA, pursuant to which we have the right to sell to YA up to $20.0 million in shares of our common stock subject to certain limitations, from time to time during 36-month period following the date of execution of the SEPA. On February 12, 2025, Indaptus issued 10,927 shares of common stock to YA as consideration for its commitment to purchase our shares of common stock under the SEPA, or the Commitment Shares, and may issue up to $20.0 million of our shares of common stock pursuant to the SEPA, or the Advance Shares. As of the date of this prospectus, we have issued an aggregate of 89,902 shares of common stock as Advance Shares to Yorkville for aggregate gross proceeds of approximately $1.85 million. In the SEPA, YA represented to Indaptus, among other things, that it was an "accredited investor", as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended, or the Securities Act. The securities were sold by us under the SEPA in reliance upon an exemption from the registration requirements under the Securities Act afforded by Section 4(a)(2) of the Securities Act.

On January 16, 2025, Indaptus completed a private placement, pursuant to which it sold and issued to certain investors 75,335 unregistered shares of common stock and unregistered warrants to purchase 75,335 shares of common stock. The warrants are immediately exercisable at an exercise price of $26.32 per share and expire five years from the date of issuance. In connection with the January 2025 financing, Indaptus issued to the placement agent and its designees placement agent warrants to purchase an aggregate of 5,268 shares of common stock at an exercise price per share equal to $32.90. The placement agent warrants are exercisable six months from the date of issuance and expire on the fifth anniversary of the issue date.

On November 25, 2024, Indaptus completed a registered direct offering, pursuant to which it sold and issued to certain investors, including an officer and director of the Company, 64,893 shares of common stock. In addition, in a concurrent private placement, Indaptus issued to the investors unregistered warrants to purchase 64,893 shares of common stock. The warrants are immediately exercisable at an exercise price of $29.40 per share and expire five years from the date of issuance. The combined purchase price for one share of common stock and one warrant was $32.90, resulting in gross proceeds of approximately $2.13 million, before deducting placement agent and other offering expenses in the amount of approximately $0.345 million. In connection with the November 2024 financing, Indaptus issued to the placement agent and its designees placement agent warrants to purchase an aggregate of 4,436 shares of common stock at an exercise price per share equal to $36.75. The placement agent warrants are exercisable six months from the date of issuance and expire on the fifth anniversary of the issue date.

On August 8, 2024, Indaptus completed a registered direct offering, pursuant to which it sold and issued to certain investors, including an officer and director of the Company, 58,708 shares of common stock. In addition, in a concurrent private placement, Indaptus issued to the investors unregistered warrants to purchase 58,708 shares of common stock. The warrants are immediately exercisable at an exercise price of $47.60 per share and expire five years from the date of issuance. The combined purchase price for one share of common stock and one warrant was $51.10, resulting in gross proceeds of approximately $3.0 million, before deducting placement agent and other offering expenses in the amount of approximately $0.5 million.

On December 22, 2022, Indaptus entered into a purchase agreement, or the Purchase Agreement, and a registration rights agreement, or the Registration Rights Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, pursuant to which Lincoln Park has committed to purchase up to $20.0 million of Indaptus' common stock. Under the terms and subject to the conditions of the Purchase Agreement, Indaptus has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $20.0 million of Indaptus' common stock. Such sales of common stock by Indaptus, if any, will be subject to certain limitations, and may occur from time to time, at Indaptus' sole discretion, over the 36-month period (unless extended to a 48-month period pursuant to the Purchase Agreement) commencing on the date that a registration statement covering the resale of shares of common stock that have been and may be issued under the Purchase Agreement, which Indaptus agreed to file with the SEC pursuant to the Registration Rights Agreement, is declared effective by the SEC and a final prospectus in connection therewith is filed and the other conditions set forth in the Purchase Agreement are satisfied. As consideration for Lincoln Park's irrevocable commitment to purchase shares of Indaptus' common stock upon the terms of and subject to satisfaction of the conditions set forth in the Purchase Agreement, upon execution of the Purchase Agreement, Indaptus (i) issued to Lincoln Park 5,087 shares of common stock, as the initial commitment shares, and (ii) will issue additional commitment shares, of common stock equal to $125,000 divided by the arithmetic average of the ten (10) Nasdaq Official Closing Prices for the common stock immediately preceding the date that Indaptus has sold over $10,000,000 purchase shares to Lincoln Park, (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction) provided that the additional commitment shares number shall be no greater than 2,722. No shares of common stock have been sold under the program and in February 2025, we terminated the purchase agreement with Lincoln Park.

The securities above were offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act since, among other things, the transactions did not involve a public offering.

**Item 16. Exhibits and Financial Statement Schedules.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Exhibits.

The exhibits to the registration statement are listed in the Exhibit Index to this registration statement and are incorporated herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Financial Statement Schedules.

All schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the financial statements and related notes thereto.

**Exhibit Index**

---

| | |
|:---|:---|
| **Exhibit No.** | **Exhibit Description** |
| 3.1 | [Amended and Restated Certificate of Incorporation of Indaptus Therapeutics, Inc., dated as of July 23, 2021 (incorporated herein by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed with the SEC on July 23, 2021)](https://www.sec.gov/Archives/edgar/data/1857044/000149315221017640/ex3-1.htm) |
| 3.2 | [Amended and Restated Bylaws of Indaptus Therapeutics, Inc., dated as of January 22, 2024 (incorporated herein by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed with the SEC on January 23, 2024)](https://www.sec.gov/Archives/edgar/data/1857044/000149315224003441/ex3-1.htm) |
| 3.3 | [Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Indaptus Therapeutics, Inc. dated August 3, 2021 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the SEC on August 6, 2021)](https://www.sec.gov/Archives/edgar/data/1857044/000149315221018935/ex3-1.htm) |
| 4.1\* | [Form of Common Warrant to be sold in the offering](https://www.sec.gov/Archives/edgar/data/1857044/000149315225012531/ex4-1.htm) |
| 4.2\* | [Form of Pre-Funded Warrant to be sold in the offering](https://www.sec.gov/Archives/edgar/data/1857044/000149315225012531/ex4-2.htm) |
| 4.3\* | [Form of Placement Agent Warrant](https://www.sec.gov/Archives/edgar/data/1857044/000149315225012531/ex4-3.htm) |
| 4.4 | [Description of Securities Registered under Section 12 (incorporated herein by reference to Exhibit 4.1 of the Company's Annual Report on Form 10-K filed with the SEC on March 21, 2021)](https://www.sec.gov/Archives/edgar/data/1857044/000149315222007319/ex4-1.htm) |
| 4.5 | [Form of Ordinary Share Purchase Warrant of Intec Parent, Inc. (incorporated herein by reference to Exhibit 10.2 to Intec Israel's Current Report on Form 8-K filed with the SEC on May 6, 2020)](https://www.sec.gov/Archives/edgar/data/1638381/000121390020011132/ea121430ex10-2_intecpharma.htm) |
| 4.6 | [Form of Series A Common Stock Purchase Warrant of Intec Parent, Inc. (incorporated herein by reference to Exhibit 10.3 to Indaptus' Current Report on Form 8-K filed with the SEC on July 29, 2021)](https://www.sec.gov/Archives/edgar/data/1857044/000149315221018114/ex10-3.htm) |

---

---

| | |
|:---|:---|
| 5.1\* | [Opinion of Greenberg Traurig LLP](https://www.sec.gov/Archives/edgar/data/1857044/000149315225012531/ex5-1.htm) |
| 10.1+ | [Indaptus Therapeutics, Inc. Amended and Restated 2021 Stock Incentive Plan (incorporated herein by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed with the SEC on June 7, 2024)](https://www.sec.gov/Archives/edgar/data/1857044/000149315224023119/ex10-1.htm) |
| 10.2+ | [Form of Option Award Agreement (incorporated herein by reference to Exhibit 10.2 of the Company's Annual Report on Form 10-K filed with the SEC on March 13, 2024)](https://www.sec.gov/Archives/edgar/data/1857044/000149315223008010/ex10-2.htm) |
| 10.3+ | [Form of Indemnification Agreement (incorporated herein by reference to Exhibit 10.5 of the Company's Current Report on Form 8-K filed with the SEC on August 6, 2021)](https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/ex10-5.htm) |
| 10.4+ | [Employment Agreement between Jeffrey Meckler and Indaptus Therapeutics, Inc., effective as of August 4, 2021 (incorporated herein by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed with the SEC on August 6, 2021)](https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/ex10-1.htm) |
| 10.5+ | [Employment Agreement between Michael J. Newman, Ph.D. and Indaptus Therapeutics, Inc., effective as of August 4, 2021 (incorporated herein by reference to Exhibit 10.2 of the Company's Current Report on Form 8-K filed with the SEC on August 6, 2021)](https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/ex10-2.htm) |
| 10.6+ | [Employment Agreement between Walt Linscott and Indaptus Therapeutics, Inc., effective as of August 4, 2021 (incorporated herein by reference to Exhibit 10.3 of the Company's Current Report on Form 8-K filed with the SEC on August 6, 2021)](https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/ex10-3.htm) |
| 10.7+ | [Employment Agreement between Nir Sassi and Indaptus Therapeutics, Inc., effective as of January 1, 2022 (incorporated herein by reference to Exhibit 10.6 of the Company's Annual Report on Form 10-K filed with the SEC on March 21, 2022)](https://www.sec.gov/Archives/edgar/data/1857044/000149315222007319/ex10-6.htm) |
| 10.8+ | [Employment Agreement between Roger J. Waltzman and Indaptus Therapeutics, Inc., effective as of August 7, 2023 (incorporated herein by reference to Exhibit 10.8 of the Company's Annual Report on Form 10-K filed with the SEC on March 13, 2024)](https://www.sec.gov/Archives/edgar/data/1857044/000149315224009769/ex10-8.htm) |
| 10.9+ | [Indaptus Therapeutics, Inc. Non-Employee Director Compensation Program (Effective April 2, 2023) (incorporated herein by reference to Exhibit 10.1 of the Company's Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023)](https://www.sec.gov/Archives/edgar/data/1857044/000149315223016268/ex10-1.htm) |
| 10.10 | [Form of Securities Purchase Agreement, dated July 23, 2021, between Intec Parent, Inc. and each purchaser identified on the signature pages hereto (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on July 29, 2021)](https://www.sec.gov/Archives/edgar/data/1857044/000149315221018114/ex10-1.htm) |
| 10.11 | [Form of Registration Rights Agreement, dated July 23, 2021, between Intec Parent, Inc. and each purchaser identified on the signature pages hereto (incorporated herein by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K filed with the SEC on July 29, 2021)](https://www.sec.gov/Archives/edgar/data/1857044/000149315221018114/ex10-4.htm) |
| 10.12 | [At the Market Offering Agreement, dated June 1, 2022, by and between Indaptus Therapeutics, Inc. and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 1.2 of the Company's Registration Statement on Form S-3 filed on September 1, 2022)](https://www.sec.gov/Archives/edgar/data/1857044/000149315222024871/ex1-2.htm) |
| 10.13 | [Purchase Agreement, dated December 22, 2022, by and between Indaptus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on December 23, 2022)](https://www.sec.gov/Archives/edgar/data/1857044/000149315222036486/ex10-1.htm) |
| 10.14 | [Registration Rights Agreement, dated December 22, 2022, by and between Indaptus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on December 23, 2022)](https://www.sec.gov/Archives/edgar/data/1857044/000149315222036486/ex10-2.htm) |
| 10.15 | [Form of Securities Purchase Agreement (incorporated herein by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed with the SEC on August 8, 2024)](https://www.sec.gov/Archives/edgar/data/1857044/000149315224030671/ex10-1.htm) |
| 10.16 | [Form of Warrant (incorporated herein by reference to Exhibit 10.2 of the Company's Current Report on Form 8-K filed with the SEC on August 8, 2024)](https://www.sec.gov/Archives/edgar/data/1857044/000149315224030671/ex10-2.htm) |
| 10.17 | [Form of Securities Purchase Agreement (incorporated herein by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed with the SEC on November 22, 2024)](https://www.sec.gov/Archives/edgar/data/1857044/000149315224047422/ex10-1.htm) |
| 10.18 | [Form of Warrant (incorporated herein by reference to Exhibit 10.2 of the Company's Current Report on Form 8-K filed with the SEC on November 22, 2024)](https://www.sec.gov/Archives/edgar/data/1857044/000149315224047422/ex10-2.htm) |
| 10.19 | [Form of Placement Agent Warrant (incorporated herein by reference to Exhibit 10.3 of the Company's Current Report on Form 8-K filed with the SEC on November 22, 2024)](https://www.sec.gov/Archives/edgar/data/1857044/000149315224047422/ex10-3.htm) |
| 10.20 | [Placement Agent Agreement, dated as of January 12, 2025, by and between Indaptus Therapeutics, Inc. and Paulson Investment Company, LLC as amended by the First Amendment to the Placement Agent Agreement, dated as of December 30, 2024 (incorporated by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K filed on January 14, 2025)](https://www.sec.gov/Archives/edgar/data/1857044/000149315225002145/ex10-4.htm) |

---

---

| | |
|:---|:---|
| 10.21 | [Form of Securities Purchase Agreement (incorporated herein by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed with the SEC on January 14, 2025)](https://www.sec.gov/Archives/edgar/data/1857044/000149315225002145/ex10-1.htm) |
| 10.22 | [Form of Warrant (incorporated herein by reference to Exhibit 10.2 of the Company's Current Report on Form 8-K filed with the SEC on January 14, 2025)](https://www.sec.gov/Archives/edgar/data/1857044/000149315225002145/ex10-2.htm) |
| 10.23 | [Form of Placement Agent Warrant (incorporated herein by reference to Exhibit 10.3 of the Company's Current Report on Form 8-K filed with the SEC on January 14, 2025)](https://www.sec.gov/Archives/edgar/data/1857044/000149315225002145/ex10-3.htm) |
| 10.24 | [Form of Standby Equity Purchase Agreement dated as of February 12, 2025 by and between the Company and YA II PN Ltd. (incorporated herein by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed with the SEC on February 12, 2025)](https://www.sec.gov/Archives/edgar/data/1857044/000149315225006052/ex10-1.htm) |
| 10.25 | [Form of Securities Purchase Agreement (filed as Exhibit 10.1 to our Report on Form 8-K filed with the SEC on June 13, 2025 and incorporated herein by reference)](https://www.sec.gov/Archives/edgar/data/1857044/000164117225014972/ex10-1.htm) |
| 10.26 | [Form of Convertible Promissory Note (filed as Exhibit 10.2 to our Report on Form 8-K filed with the SEC on June 13, 2025 and incorporated herein by reference)](https://www.sec.gov/Archives/edgar/data/1857044/000164117225014972/ex10-2.htm) |
| 10.27 | [Form of Pre-Funded Warrant (filed as Exhibit 10.3 to our Report on Form 8-K filed with the SEC on June 13, 2025 and incorporated herein by reference)](https://www.sec.gov/Archives/edgar/data/1857044/000164117225014972/ex10-3.htm) |
| 10.28 | [Form of Common Warrant (filed as Exhibit 10.3 to our Form S-3 filed with the SEC on August 13, 2025 and incorporated herein by reference)](https://www.sec.gov/Archives/edgar/data/1857044/000164117225023499/ex10-3.htm) |
| 10.29 | [Form of Placement Agent Agreement (filed as Exhibit 10.4 to our Report on Form 8-K filed with the SEC on June 13, 2025 and incorporated herein by reference)](https://www.sec.gov/Archives/edgar/data/1857044/000164117225014972/ex10-4.htm) |
| 10.30\* | [Form of Securities Purchase Agreement](https://www.sec.gov/Archives/edgar/data/1857044/000149315225012531/ex10-30.htm) |
| 10.31\*\* | [Engagement Agreement dated March 16, 2025, between Indaptus Therapeutics, Inc. and H.C. Wainwright & Co., LLC](ex10-31.htm) |
| 21.1 | [List of Subsidiaries (incorporated herein by reference to Exhibit 21.1 to the Company's Annual Report on Form 10-K filed with the SEC on March 13, 2024)](https://www.sec.gov/Archives/edgar/data/1857044/000149315222007319/ex21-1.htm) |
| 23.1\* | [Consent of Haskell & White LLP, independent registered public accounting firm](https://www.sec.gov/Archives/edgar/data/1857044/000149315225012531/ex23-1.htm) |
| 23.2\* | [Consent of Greenberg Traurig LLP (included in Exhibit 5.1)](https://www.sec.gov/Archives/edgar/data/1857044/000149315225012531/ex5-1.htm) |
| 24.1 | [Power of Attorney (included on signature page)](#pa_002) |
| 107\* | [Filing Fee Table](https://www.sec.gov/Archives/edgar/data/1857044/000149315225012531/ex107.htm) |

---

\* Previously filed. <br> \*\* Filed herewith. <br> + Indicates management contract or compensatory plan.

**Item 17. Undertakings**

(a) The
 undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To
 file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To
 include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

(ii) To
 reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
 post- effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
 forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
 the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end
 of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b)
 if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set
 forth in the "Calculation of Registration Fee" table in the effective registration statement;

(iii) To
 include any material information with respect to the plan of distribution not previously disclosed in the registration statement
 or any material change to such information in the registration statement;

provided, however, that: Paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act, that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That,
 for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
 to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
 be deemed to be the initial bona fide offering thereof.

(3) To
 remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
 termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) That,
 for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Each
 prospectus filed by the registrant pursuant to Rule 424(b)(3) (§ 230.424(b)(3) of this chapter) shall be deemed to be part of
 the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

(ii) Each
 prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) (§ 230.424(b)(2), (b)(5), or (b)(7) of this chapter)
 as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or
 (x) (§ 230.415(a)(1)(i), (vii), or (x) of this chapter) for the purpose of providing the information required by section 10(a)
 of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date
 such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering
 described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an
 underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the
 registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the
 initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part
 of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement
 or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective
 date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
 statement or made in any such document immediately prior to such effective date.

(b) That,
 for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
 of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
 to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
 are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller
 to the purchaser and will be considered to offer or sell such securities to such purchaser:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) any other communication that is an offer in the offering made by the undersigned registrant to the purchaser;

(c) That,
 for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant
 to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's
 annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration
 statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
 securities at that time shall be deemed to be the initial bona fide offering thereof.

(d) Insofar
 as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
 of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the
 Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore,
 unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of
 expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action,
 suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
 the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court
 of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities
 Act and will be governed by the final adjudication of such issue.

(e) The
 undersigned registrant hereby undertakes that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of New York, NY, on the 3<sup>rd</sup> day of September, 2025.

---

| | |
|:---|:---|
| **INDAPTUS THERAPEUTICS, INC.** | **INDAPTUS THERAPEUTICS, INC.** |
| By: | */s/ Jeffrey A. Meckler* |
| Name: | Jeffrey A. Meckler |
| Title: | Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| */s/ Jeffrey A. Meckler* | Chief Executive Officer and Director | September 3, 2025 |
| Jeffrey A. Meckler | (principal executive officer) |  |
| */s/ Nir Sassi* | Chief Financial Officer | September 3, 2025 |
| Nir Sassi | (principal financial officer and principal accounting officer) |  |
| */s/ \** | Chief Scientific Officer and Director | September 3, 2025 |
| Michael J. Newman, Ph.D. |  |  |
| */s/ \** | Chairman | September 3, 2025 |
| Dr. Roger J. Pomerantz |  |  |
| */s/ \** | Director | September 3, 2025 |
| William B. Hayes |  |  |
| */s/ \** | Director | September 3, 2025 |
| Hila Karah |  |  |
| */s/ \** | Director | September 3, 2025 |
| Anthony J. Maddaluna |  |  |
| */s/ \** | Director | September 3, 2025 |
| Mark J. Gilbert |  |  |
| */s/ \** | Director | September 3, 2025 |
| Robert E. Martell, M.D., Ph.D. |  |  |

---

---

| |
|:---|
| \* */s/ Jeffrey A. Meckler* |
| Jeffrey A. Meckler<br> Attorney in Fact |

---

## Exhibit 10.31

**Exhibit 10.31**

**Execution Version**

March 16, 2025

<u>STRICTLY CONFIDENTIAL</u>

Indaptus Therapeutics, Inc.

3 Columbus Circle, 15th Floor

New York, NY 10019

Attn: Jeffrey A. Meckler, Chief Executive Officer

Dear Mr. Meckler:

This letter agreement (this "<u>Agreement</u>") constitutes the agreement between Indaptus Therapeutics, Inc. (the "<u>Company</u>") and H.C. Wainwright & Co., LLC ("<u>Wainwright</u>"), that Wainwright shall serve as the exclusive underwriter, agent or advisor in any offering (each, an "<u>Offering</u>") of securities of the Company (the "<u>Securities</u>") during the Term (as hereinafter defined) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright's assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright in connection with an Offering. The Company expressly acknowledges and agrees that Wainwright's involvement in an Offering is strictly on a reasonable best efforts basis and that the consummation of an Offering will be subject to, among other things, market conditions. The execution of this Agreement does not constitute a commitment by Wainwright to purchase the Securities and does not ensure a successful Offering of the Securities or the success of Wainwright with respect to securing any other financing on behalf of the Company. Wainwright may retain other underwriters, brokers, dealers or agents on its behalf in connection with an Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. <u>Compensation; Reimbursement</u>. The Company shall compensate Wainwright as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. *Cash Fee*. The Company shall pay Wainwright a cash fee, or as to an underwritten Offering an
 underwriter discount, equal to 7.0% of the aggregate gross proceeds raised at each closing
 of each Offering (each, a " <u>Closing</u> ").

430 Park Avenue \| New York, New York 10022 \| 212.356.0500 \| www.hcwco.com

Member: FINRA/SIPC

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. *Warrant Coverage*. The Company shall issue to Wainwright or its designees at each Closing, warrants
 (the " <u>Wainwright Warrants</u> ") to purchase that number of shares of common
 stock of the Company equal to 6.0% of the aggregate number of shares of common stock (or
 common stock equivalent, if applicable) placed in each Offering (and if an Offering includes
 a "greenshoe" or "additional investment" component, such number of
 shares of common stock underlying such "greenshoe" or "additional investment"
 component, with the Wainwright Warrants issuable upon the exercise of such component). If
 the Securities included in an Offering are convertible, the Wainwright Warrants shall be
 determined by dividing the gross proceeds raised in such Offering by the Offering Price (as
 defined hereunder). The Wainwright Warrants shall be in a customary form reasonably acceptable
 to Wainwright, have a term of five (5) years and an exercise price equal to 125% of the offering
 price per share (or unit, if applicable) in the applicable Offering and if such offering
 price is not available, the market price of the common stock on the date an Offering is commenced
 (such price, the " <u>Offering Price</u> "). If warrants are issued to investors
 in an Offering, the Wainwright Warrants shall have the same terms as the warrants issued
 to investors in the applicable Offering, except that such Wainwright Warrants shall have
 an exercise price equal to 125% of the Offering Price.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. *Expense Allowance*. Out of the proceeds of each Closing, the Company also agrees to pay Wainwright
 (a) a management fee equal to 1.0% of the gross proceeds raised in each Offering; (b) $25,000
 for non-accountable expenses (to be increased to $50,000 in case a public Offering is contemplated
 or consummated); (c) up to $50,000 for fees and expenses of legal counsel and other out-of-pocket
 expenses (to be increased to $100,000 in case a public Offering is contemplated or consummated);
 plus the additional amount payable by the Company pursuant to Paragraph D.3 hereunder and,
 if applicable, the costs associated with the use of a third-party electronic road show service
 (such as NetRoadshow); provided, however, that such amounts in no way limit or impair the
 indemnification and contribution provisions of this Agreement. A "public Offering"
 as used herein shall bear the same meaning as a public offering under IM-5635-3 of the Nasdaq
 Stock Market LLC Rules with respect the manner of marketing and distribution of such Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. *Tail*.
 Wainwright shall be entitled to compensation under clauses (1) and (2) hereunder, calculated
 in the manner set forth therein, with respect to any public or private offering or other
 financing or capital-raising transaction of any kind (" <u>Tail Financing</u> ")
 to the extent that any capital or funds in such Tail Financing is provided to the Company
 directly or indirectly by investors whom (i) Wainwright had contacted during the Term or
 introduced to the Company during the Term in connection with a public Offering, and (ii)
 Wainwright had brought "over the wall" during the Term, if such Tail Financing
 is consummated at any time within the 12-month period following the expiration or termination
 of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. *Right of First Refusal*. If, from the date hereof until the 12-month anniversary following consummation
 of each Offering (subject to FINRA Rule 5110(g)(6)(A)), the Company or any of its subsidiaries
 decides to raise funds by means of a public offering (including at- the-market facility)
 or a private placement or any other capital-raising financing of equity, equity-linked or
 debt securities, excluding any Strategic Transaction (as defined below), Wainwright (or any
 affiliate designated by Wainwright) shall have the right to act as sole book-running manager,
 sole underwriter or sole placement agent for such financing. If Wainwright or one of its
 affiliates decides to accept any such engagement, the agreement governing such engagement
 will contain, among other things, provisions for customary fees for transactions of similar
 size and nature and the provisions of this Agreement, including indemnification, which are
 appropriate to such a transaction. For the purpose of this Agreement, a Strategic Transaction
 means an acquisition, merger or strategic transaction which is with a person not introduced
 to the Company or contacted by Wainwright in connection with an Offering hereunder; provided
 that any such transaction shall only be to a person (or to the equity holders of a person)
 which is, itself or through its subsidiaries and/or affiliates, an operating company or an
 owner of an asset synergistic with the business of the Company, and, through one or more
 of a series of transactions, shall provide to the Company additional benefits in addition
 to the investment of funds, but shall not include a transaction in which the Company is issuing
 securities primarily for the purpose of raising capital or to an entity whose primary business
 is investing in securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. <u>Term and Termination of Engagement; Exclusivity</u>. The term of Wainwright's exclusive engagement will begin on the date hereof and end forty-five (45) days thereafter (the "<u>Initial Term</u>"); provided, however, that if an Offering is consummated within the Initial Term, the term of this Agreement shall be extended by an additional forty-five (45) day period (the "<u>Extension Term</u>," and together with the Initial Term, the "<u>Term</u>"). For clarity, the term "Term" shall mean the Initial Term if there is no Extension Term. Notwithstanding anything to the contrary contained herein, the Company agrees that the provisions relating to the payment of fees, reimbursement of expenses, right of first refusal, tail, indemnification and contribution, confidentiality, conflicts, independent contractor and waiver of the right to trial by jury will survive any termination or expiration of this Agreement. Notwithstanding anything to the contrary contained herein, the Company has the right to terminate the Agreement for cause in compliance with FINRA Rule 5110(g)(5)(B)(i). The exercise of such right of termination for cause eliminates the Company's obligations with respect to the provisions relating to the tail fees and right of first refusal. Notwithstanding anything to the contrary contained in this Agreement, in the event that an Offering pursuant to this Agreement shall not be carried out for any reason whatsoever during the Term, the Company shall be obligated to pay to Wainwright its actual and accountable out-of-pocket expenses related to an Offering (including the fees and disbursements of Wainwright's legal counsel) and, if applicable, for electronic road show service used in connection with an Offering, up to an amount not to exceed $50,000. During Wainwright's engagement hereunder: (i) the Company will not, and will not permit its representatives to, other than in coordination with Wainwright, contact or solicit institutions, corporations or other entities or individuals as potential purchasers of the Securities or investment banks in connection with an Offering and (ii) the Company will not pursue any financing transaction which would be in lieu of an Offering. Furthermore, the Company agrees that during Wainwright's engagement hereunder, all inquiries from prospective investors will be referred to Wainwright. Additionally, except as set forth hereunder, the Company represents, warrants and covenants that no brokerage or finder's fees or commissions are or will be payable by the Company or any subsidiary of the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other third-party with respect to any Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. <u>Information; Reliance</u>. The Company shall furnish, or cause to be furnished, to Wainwright all information requested by Wainwright for the purpose of rendering services hereunder and conducting due diligence (all such information being the "<u>Information</u>"). In addition, the Company agrees to make available to Wainwright upon request from time to time the officers, directors, accountants, counsel and other advisors of the Company. The Company recognizes and confirms that Wainwright (a) will use and rely on the Information, including any documents provided to investors in each Offering (the "<u>Offering Documents</u>") which shall include any Purchase Agreement (as defined hereunder), and on information available from generally recognized public sources in performing the services contemplated by this Agreement without having independently verified the same; (b) does not assume responsibility for the accuracy or completeness of the Offering Documents or the Information and such other information; and (c) will not make an appraisal of any of the assets or liabilities of the Company. Upon reasonable request, the Company will meet with Wainwright or its representatives to discuss all information relevant for disclosure in the Offering Documents and will cooperate in any investigation undertaken by Wainwright thereof, including any document included or incorporated by reference therein. At each Offering, at the request of Wainwright, the Company shall deliver such legal letters (including, without limitation, negative assurance letters), opinions, comfort letters, officers' and secretary certificates and good standing certificates, all in form and substance satisfactory to Wainwright and its counsel as is customary for such Offering. Wainwright shall be a third party beneficiary of any representations, warranties, covenants, closing conditions and closing deliverables made by the Company in any Offering Documents, including representations, warranties, covenants, closing conditions and closing deliverables made to any investor in an Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. <u>Related Agreements</u>. At each Offering, the Company shall enter into the following additional agreements, as applicable:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. *Underwritten Offering*. If an Offering is an underwritten Offering, the Company and Wainwright shall
 enter into a customary underwriting agreement in form and substance satisfactory to Wainwright
 and its counsel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. *Best Efforts Offering*. If an Offering is on a best efforts basis, the sale of Securities to
 the investors in the Offering will be evidenced by a purchase agreement (" <u>Purchase Agreement</u> ") between the Company and such investors in a form reasonably satisfactory
 to the Company and Wainwright. Wainwright shall be a third party beneficiary with respect
 to the representations, warranties, covenants, closing conditions and closing deliverables
 included in the Purchase Agreement. Prior to the signing of any Purchase Agreement, officers
 of the Company with responsibility for financial affairs will be available to answer inquiries
 from prospective investors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. *Escrow, Settlement and Closing*. If each Offering is not settled via delivery versus payment (" <u>DVP</u> "),
 the Company and Wainwright shall enter into an escrow agreement with a third party escrow
 agent pursuant to which Wainwright's compensation and expenses shall be paid from the
 gross proceeds of the Securities sold. If the Offering is settled in whole or in part via
 DVP, Wainwright shall arrange for its clearing agent to provide the funds to facilitate such
 settlement; provided, however, if the clearing firm provides the funds in a best efforts
 offering and subsequent to such delivery an investor fails to provide the necessary funds
 to the clearing agent for such purchase of Securities, Wainwright shall instruct the clearing
 agent to promptly return any such Securities to the Company and the Company shall promptly
 return such investor's purchase price to the clearing agent. The Company shall pay
 Wainwright closing costs, which shall also include the reimbursement of the out-of-pocket
 cost of the escrow agent or clearing agent, as applicable, which closing costs shall not
 exceed $15,950.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. *FINRA Amendments*. Notwithstanding anything herein to the contrary, in the event that Wainwright
 determines that any of the terms provided for hereunder shall not comply with a FINRA rule,
 including but not limited to FINRA Rule 5110, then the Company shall agree to amend this
 Agreement (or include such revisions in the final underwriting agreement) in writing upon
 the request of Wainwright to comply with any such rules; provided that any such amendments
 shall not provide for terms that are less favorable to the Company than are reflected in
 this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;E. <u>Confidentiality</u>. In the event of the consummation or public announcement of any Offering, Wainwright shall have the right to disclose its participation in such Offering, including, without limitation, the Offering at its cost of "tombstone" advertisements in financial and other newspapers and journals.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;F. <u>Indemnity</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. In
 connection with the Company's engagement of Wainwright hereunder, the Company hereby
 agrees to indemnify and hold harmless Wainwright and its affiliates, and the respective controlling
 persons, directors, officers, members, shareholders, agents and employees of any of the foregoing
 (collectively the " <u>Indemnified Persons</u> "), from and against any and all
 claims, actions, suits, proceedings (including those of shareholders), damages, liabilities
 and expenses incurred by any of them (including the reasonable fees and expenses of counsel),
 as incurred, whether or not the Company is a party thereto (collectively a " <u>Claim</u> "),
 that are (A) related to or arise out of (i) any actions taken or omitted to be taken (including
 any untrue statements made or any statements omitted to be made) by the Company, or (ii)
 any actions taken or omitted to be taken by any Indemnified Person in connection with the
 Company's engagement of Wainwright, or (B) otherwise relate to or arise out of Wainwright's
 activities on the Company's behalf under Wainwright's engagement, and the Company
 shall reimburse any Indemnified Person for all expenses (including the reasonable fees and
 expenses of counsel) as incurred by such Indemnified Person in connection with investigating,
 preparing or defending any such claim, action, suit or proceeding, whether or not in connection
 with pending or threatened litigation in which any Indemnified Person is a party. The Company
 will not, however, be responsible for any Claim that is finally judicially determined to
 have resulted from the gross negligence or willful misconduct of any such Indemnified Person
 for such Claim. The Company further agrees that no Indemnified Person shall have any liability
 to the Company for or in connection with the Company's engagement of Wainwright except
 for any Claim incurred by the Company as a result of such Indemnified Person's gross
 negligence or willful misconduct.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The
 Company further agrees that it will not, without the prior written consent of Wainwright,
 settle, compromise or consent to the entry of any judgment in any pending or threatened Claim
 in respect of which indemnification may be sought hereunder (whether or not any Indemnified
 Person is an actual or potential party to such Claim), unless such settlement, compromise
 or consent includes an unconditional, irrevocable release of each Indemnified Person from
 any and all liability arising out of such Claim.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Promptly
 upon receipt by an Indemnified Person of notice of any complaint or the assertion or institution
 of any Claim with respect to which indemnification is being sought hereunder, such Indemnified
 Person shall notify the Company in writing of such complaint or of such assertion or institution
 but failure to so notify the Company shall not relieve the Company from any obligation it
 may have hereunder, except and only to the extent such failure results in the forfeiture
 by the Company of substantial rights and defenses. If the Company is requested by such Indemnified
 Person, the Company will assume the defense of such Claim, including the employment of counsel
 for such Indemnified Person and the payment of the fees and expenses of such counsel, provided,
 however, that such counsel shall be satisfactory to the Indemnified Person and provided further
 that if the legal counsel to such Indemnified Person reasonably determines that the use of
 counsel chosen by the Company to represent such Indemnified Person would present such counsel
 with a conflict of interest or if the defendant in, or target of, any such Claim, includes
 an Indemnified Person and the Company, and legal counsel to such Indemnified Person reasonably
 concludes that there may be legal defenses available to it or other Indemnified Persons different
 from or in addition to those available to the Company, such Indemnified Person will employ
 its own separate counsel (including local counsel, if necessary) to represent or defend him,
 her or it in any such Claim and the Company shall pay the reasonable fees and expenses of
 such counsel. If such Indemnified Person does not request that the Company assume the defense
 of such Claim, such Indemnified Person will employ its own separate counsel (including local
 counsel, if necessary) to represent or defend him, her or it in any such Claim and the Company
 shall pay the reasonable fees and expenses of such counsel. Notwithstanding anything herein
 to the contrary, if the Company fails timely or diligently to defend, contest, or otherwise
 protect against any Claim, the relevant Indemnified Person shall have the right, but not
 the obligation, to defend, contest, compromise, settle, assert crossclaims, or counterclaims
 or otherwise protect against the same, and shall be fully indemnified by the Company therefor,
 including without limitation, for the reasonable fees and expenses of its counsel and all
 amounts paid as a result of such Claim or the compromise or settlement thereof. In addition,
 with respect to any Claim in which the Company assumes the defense, the Indemnified Person
 shall have the right to participate in such Claim and to retain his, her or its own counsel
 therefor at his, her or its own expense.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The
 Company agrees that if any indemnity sought by an Indemnified Person hereunder is held by
 a court to be unavailable for any reason then (whether or not Wainwright is the Indemnified
 Person), the Company and Wainwright shall contribute to the Claim for which such indemnity
 is held unavailable in such proportion as is appropriate to reflect the relative benefits
 to the Company, on the one hand, and Wainwright on the other, in connection with Wainwright's
 engagement referred to above, subject to the limitation that in no event shall the amount
 of Wainwright's contribution to such Claim exceed the amount of fees actually received
 by Wainwright from the Company pursuant to Wainwright's engagement. The Company hereby
 agrees that the relative benefits to the Company, on the one hand, and Wainwright on the
 other, with respect to Wainwright's engagement shall be deemed to be in the same proportion
 as (a) the total value paid or proposed to be paid or received by the Company pursuant to
 the applicable Offering (whether or not consummated) for which Wainwright is engaged to render
 services bears to (b) the fee paid or proposed to be paid to Wainwright in connection with
 such engagement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The
 Company's indemnity, reimbursement and contribution obligations under this Agreement
 (a) shall be in addition to, and shall in no way limit or otherwise adversely affect any
 rights that any Indemnified Person may have at law or at equity and (b) shall be effective
 whether or not the Company is at fault in any way.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;G. <u>Limitation of Engagement to the Company</u>. The Company acknowledges that Wainwright has been retained only by the Company, that Wainwright is providing services hereunder as an independent contractor (and not in any fiduciary or agency capacity) and that the Company's engagement of Wainwright is not deemed to be on behalf of, and is not intended to confer rights upon, any shareholder, owner or partner of the Company or any other person not a party hereto as against Wainwright or any of its affiliates, or any of its or their respective officers, directors, controlling persons (within the meaning of Section 15 of the Securities Act of 1933, as amended (the "<u>Securities Act</u>") or Section 20 of the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>")), employees or agents. Unless otherwise expressly agreed in writing by Wainwright, no one other than the Company is authorized to rely upon this Agreement or any other statements or conduct of Wainwright, and no one other than the Company is intended to be a beneficiary of this Agreement. The Company acknowledges that any recommendation or advice, written or oral, given by Wainwright to the Company in connection with Wainwright's engagement is intended solely for the benefit and use of the Company's management and directors in considering a possible Offering, and any such recommendation or advice is not on behalf of, and shall not confer any rights or remedies upon, any other person or be used or relied upon for any other purpose. Wainwright shall not have the authority to make any commitment binding on the Company. The Company, in its sole discretion, shall have the right to reject any investor introduced to it by Wainwright.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;H. <u>Limitation of Wainwright's Liability to the Company</u>. Wainwright and the Company further agree that neither Wainwright nor any of its affiliates or any of its or their respective officers, directors, controlling persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act), employees or agents shall have any liability to the Company, its security holders or creditors, or any person asserting claims on behalf of or in the right of the Company (whether direct or indirect, in contract, tort, for an act of negligence or otherwise) for any losses, fees, damages, liabilities, costs, expenses or equitable relief arising out of or relating to this Agreement or the services rendered hereunder, except for losses, fees, damages, liabilities, costs or expenses that arise out of or are based on any action of or failure to act by Wainwright and that are finally judicially determined to have resulted solely from the gross negligence or willful misconduct of Wainwright.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I. <u>Governing Law</u>. This Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be fully performed therein. Any disputes that arise under this Agreement, even after the termination of this Agreement, will be heard only in the state or federal courts located in the City of New York, State of New York. The parties hereto expressly agree to submit themselves to the jurisdiction of the foregoing courts in the City of New York, State of New York. The parties hereto expressly waive any rights they may have to contest the jurisdiction, venue or authority of any court sitting in the City and State of New York. In the event Wainwright or any Indemnified Person is successful in any action, or suit against the Company, arising out of or relating to this Agreement, the final judgment or award entered shall be entitled to have and recover from the Company the costs and expenses incurred in connection therewith, including its reasonable attorneys' fees. Any rights to trial by jury with respect to any such action, proceeding or suit are hereby waived by Wainwright and the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;J. <u>Notices</u>. All notices hereunder will be in writing and sent by certified mail, hand delivery, overnight delivery or e-mail, if sent to Wainwright, at the address set forth on the first page hereof, e-mail: notices@hcwco.com, Attention: Head of Investment Banking, and if sent to the Company, to the address set forth on the first page hereof, e-mail: Jeffrey@indaptusrx.com, Attention: Chief Executive Officer. Notices sent by certified mail shall be deemed received five days thereafter, notices sent by hand delivery or overnight delivery shall be deemed received on the date of the relevant written record of receipt, notices sent by e-mail shall be deemed received as of the date and time they were sent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;K. <u>Conflicts</u>. The Company acknowledges that Wainwright and its affiliates may have and may continue to have investment banking and other relationships with parties other than the Company pursuant to which Wainwright may acquire information of interest to the Company. Wainwright shall have no obligation to disclose such information to the Company or to use such information in connection with any contemplated transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;L. <u>Anti-Money Laundering</u>. To help the United States government fight the funding of terrorism and money laundering, the federal laws of the United States require all financial institutions to obtain, verify and record information that identifies each person with whom they do business. This means Wainwright must ask the Company for certain identifying information, including a government-issued identification number (e.g., a U.S. taxpayer identification number) and such other information or documents that Wainwright considers appropriate to verify the Company's identity, such as certified articles of incorporation, a government-issued business license, a partnership agreement or a trust instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;M. <u>Miscellaneous</u>. The Company represents and warrants that it has all requisite power and authority to enter into and carry out the terms and provisions of this Agreement and the execution, delivery and performance of this Agreement does not breach or conflict with any agreement, document or instrument to which it is a party or bound. Furthermore, the Company represents and warrants that no consent, permit, waiver, approval or authorization of any third party in connection with the execution, delivery and performance by the Company of this Agreement or an Offering, is required or has not been obtained. This Agreement shall not be modified or amended except in writing signed by Wainwright and the Company. This Agreement shall be binding upon and inure to the benefit of both Wainwright and the Company and their respective assigns, successors, and legal representatives. This Agreement constitutes the entire agreement of Wainwright and the Company with respect to the subject matter hereof and supersedes any prior agreements with respect to the subject matter hereof. If any provision of this Agreement is determined to be invalid or unenforceable in any respect, such determination will not affect such provision in any other respect, and the remainder of the Agreement shall remain in full force and effect. This Agreement may be executed in counterparts (including electronic counterparts), each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Signatures to this Agreement transmitted by electronic mail in "portable document format" (.pdf) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature. The undersigned hereby consents to receipt of this Agreement in electronic form and understands and agrees that this Agreement may be signed electronically. In the event that any signature is delivered by electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or otherwise by electronic transmission evidencing an intent to sign this Agreement, such electronic mail or other electronic transmission shall create a valid and binding obligation of the undersigned with the same force and effect as if such signature were an original. Execution and delivery of this Agreement by electronic mail or other electronic transmission is legal, valid and binding for all purposes.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

In acknowledgment that the foregoing correctly sets forth the understanding reached by Wainwright and the Company, please sign in the space provided below, whereupon this letter shall constitute a binding Agreement as of the date indicated above.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **H.C. WAINWRIGHT & CO., LLC** | **H.C. WAINWRIGHT & CO., LLC** |
| By: | /s/ Mark W. Viklund |
| Name: | Mark W. Viklund |
| Title: | Chief Executive Officer |
| Date: | <br> March 16, 2025 |

---

---

| | |
|:---|:---|
| Accepted and Agreed: | Accepted and Agreed: |
| **INDAPTUS THERAPEUTICS, INC.** | **INDAPTUS THERAPEUTICS, INC.** |
| By: | /s/ Nir Sassi |
| Name: | Nir Sassi |
| Title: | CFO |

---